Pharmaceutical - Isis Pharmaceuticals

Filter

Current filters:

Isis Pharmaceuticals

Popular Filters

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

Another $1 million GSK milestone for Isis Pharma

Another $1 million GSK milestone for Isis Pharma

24-06-2014

USA-based Isis Pharmaceuticals said today that it has earned a $1 million milestone payment from GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR RxPharmaceuticalRare diseasesResearch

ISIS Pharma earns $1 million from GSK for advancing ISIS-TTRRx

03-03-2014

USA-based Isis Pharmaceuticals has earned a $1 million milestone payment from UK pharma giant GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTRRxPharmaceuticalRare diseasesResearch

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard

10-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

$10M milestone for Isis Pharma from AstraZeneca for ISIS-ARRx to treat prostate cancer

04-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says that Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AstraZenecaIsis PharmaceuticalsISIS-AR rxLicensingOncologyPharmaceutical

Roche and Isis Pharma in up to $392 million deal on Huntington's research

09-04-2013

Swiss drug major Roche (ROG: SIX) and USA-based Isis Pharmaceuticals (Nasdaq: ISIS) have formed an alliance…

Isis PharmaceuticalsLicensingMarkets & MarketingPharmaceuticalRare diseasesResearchRoche

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions

17-12-2012

French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Genzyme and Isis file Kynamro NDA in USA

02-04-2012

Biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN), has submitted a New Drug…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Isis sees Kynamro delay; adds new drugs to pipeline

15-12-2011

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamromipomersenNephrology and HepatologyPharmaceuticalRegulationResearchSanofi

Pfizer to buy Excaliard, gaining rights to Ph II skin scarring product

23-11-2011

Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire…

DermatologicalsExcaliard PharmaIsis PharmaceuticalsMergers & AcquisitionsPfizerPharmaceutical

Company Spotlight

ImmunoGen

ImmunoGen

Back to top